Clinical Trials

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

557 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT02061085 2025-06-08

MERIBEL

53 enrolled 11 charts

Breast Neoplasms, Ketosis, Neoplasm Metastasis

NCT03222856 2025-06-05

KELLY

44 enrolled 17 charts

Breast Neoplasms

NCT01827787 2024-11-06

Eribulin in HER2 Negative Metastatic BrCa

83 enrolled 18 charts

Breast Neoplasms

NCT02681523 2024-09-19

ALERT

8 enrolled 20 charts

Breast Neoplasms

NCT02037529 2024-08-20

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

Phase 3 Suspended

201 enrolled 19 charts

Breast Neoplasms

NCT03786094 2023-11-01

FORTRESS

Phase 3 Terminated

432 enrolled 13 charts

Breast Neoplasms

NCT00879086 2023-06-22

A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer

104 enrolled 16 charts

Breast Neoplasms, Neoplasms

NCT01268150 2023-06-22

A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

56 enrolled 10 charts

Breast Neoplasms

NCT01269346 2023-06-22

Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer

52 enrolled 9 charts

Breast Neoplasms

NCT01439282 2023-06-22

Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

77 enrolled 9 charts

Breast Neoplasms

NCT02915744 2023-04-14

ATTAIN

178 enrolled 37 charts

Breast Neoplasms, Carcinoma, Neoplasm Metastasis

NCT02120469 2022-07-05

Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer

Phase 1 Completed

27 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02574455 2022-06-15

ASCENT

529 enrolled 23 charts 1 FDA

Breast Neoplasms

NCT02000596 2022-05-27

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

2 enrolled 7 charts

Breast Neoplasms

NCT02513472 2022-05-05

ENHANCE-1

258 enrolled 18 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01705691 2021-10-06

Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer

50 enrolled 14 charts

Breast Neoplasms

NCT01593020 2021-09-22

Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2

54 enrolled 10 charts

Breast Neoplasms

NCT01554371 2021-02-03

Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies

44 enrolled 14 charts

Breast Neoplasms, Carcinoma

NCT01323530 2021-01-11

A Confirmation Study of Eribulin in Combination With Capecitabine

76 enrolled 24 charts

Breast Neoplasms

NCT02581839 2020-07-30

Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate

9 enrolled 14 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT01908101 2020-07-23

Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer

86 enrolled 10 charts

Breast Neoplasms

NCT01596751 2020-07-17

Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer

67 enrolled 19 charts

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT02753595 2020-07-13

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

Phase 1/2 Terminated

25 enrolled 9 charts

Breast Neoplasms

NCT00337103 2020-06-18

E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

1,276 enrolled 22 charts

Breast Neoplasms

NCT00388726 2020-01-07

E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer

762 enrolled 12 charts

Breast Neoplasms

NCT01328249 2019-08-20

Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer

81 enrolled 9 charts

Breast Neoplasms

NCT01912963 2018-12-05

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

32 enrolled 15 charts

Breast Neoplasms

NCT02481050 2018-11-15

Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer

58 enrolled 14 charts

Breast Neoplasms

NCT01401959 2018-06-15

Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy

127 enrolled 11 charts

Breast Neoplasms, Neoplasm, Residual

NCT01527487 2016-11-04

Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer

76 enrolled 8 charts

Breast Neoplasms

NCT01961544 2016-10-07

ESKIMO

Phase 4 Completed

101 enrolled 6 charts

Breast Neoplasms, Neoplasm Metastasis

NCT01498588 2016-10-03

Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

7 enrolled 7 charts

Breast Neoplasms

NCT00246090 2014-07-14

A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine

298 enrolled 8 charts

Breast Neoplasms

NCT01142661 2013-09-20

Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies

Phase NA Completed

9 enrolled 8 charts

Breast Neoplasms

NCT00965523 2013-08-15

Study of E7389 for Advanced or Metastatic Breast Cancer

81 enrolled 7 charts

Breast Neoplasms, Neoplasms

NCT00097721 2013-04-22

A Study of E7389 in Advanced/Metastatic Breast Cancer Patients

104 enrolled 12 charts